India’s first Corona vaccine update: Covaxin trial begins well in 2 hospitals

India’s first Corona vaccine update: Covaxin trial begins well in 2 hospitals.

With the increasing number of novel coronavirus cases growing at a daily high in the country for the past few days, COVAXIN, India’s first indigenous COVID-19 vaccine, received approval from the AIIMS Ethics Committee on Saturday to begin human trials from Monday. AIIMS-Delhi is one of the 12 sites selected by the Indian Council of Medical Research (ICMR) for conducting Phase I and II human trials of Covaxin.

In Phase I, the vaccine will be tested on 375 volunteers and maximum of them will be of 100 AIIMS. In addition, the human dose of the vaccine developed by Bharat Biotech India (BBIL), in collaboration with ICMR’s National Institute of Virology (NIV), also started on Wednesday, with the vaccine being given to participants from All India Institute of Medical Sciences, Patna and Pandit Bhagwat. is. Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS) in Rohtak, Haryana, a spokesperson said in a statement on Friday, according to the Mint report.

The biotech company received approval from the Drugs Controller General of India (DCGI) earlier this month for human clinical trials.

Here are the major updates that we know about India’s first indigenous COVID-19 vaccine candidate so far:

1) The AIIMS Ethics Committee gave its approval for a human clinical trial starting tomorrow. “Healthy volunteers with no co-morbid conditions and without a history of COVID-19 who are over 18 and under 55 will be eligible to participate in a randomized, double-blind, placebo-controlled clinical trial , “Dr. Sanjay Rai, Professor at the Center for Community Medicine in AIIMS. He said anyone wishing to participate in the trial could send an email to Ctaiims.covid19@gmail.com or call 7428847499.

2) Human trials of COVAXIN have started at All India Institute of Medical Sciences, Patna. AIIMS-Patna selected 10 volunteers to begin human trials of covaxin.

3) AIIMS Patna was the first institute to begin testing on Wednesday and so far around nine people have been vaccinated with a small dose to check for safety, two sources said on condition of anonymity. Sources said that after two weeks, if the vaccine is found to be safe, it will be given to more people.

4) Testing has so far started in AIIMS, Patna, and a few more sites. Earlier, Haryana Health Minister Anil Vij tweeted that human trials with Bharat Biotech’s coronavirus vaccine ov covaxin ‘also started in PGIMS Rohtak. All have tolerated the vaccine very well. There were no adverse efforts, ”Vij tweeted.

5) Sources in Bharat Biotech said that the human clinical trial for COVAXIN was started nationwide with 375 volunteers.

6) COVAXIN has been obtained from a stretch of isolated novel coronaviruses by the National Institute of Virology in Pune. Bharat Biotech developed an “inactive” vaccine at its high-control facility in Gnome Valley, Hyderabad.

7) “Once a vaccine is injected into a human, it has no ability to infect or replicate the infected virus, as it is a killed virus. It just acts on the immune system as a dead virus and An antibody responds to the virus, ”the company said.

8) On Thursday, Microsoft co-founder and philanthropist Bill Gates claimed that the Indian pharmaceutical industry would be able to produce the COVID-19 vaccine not only for the country, but also for the entire world. He said, “India has a lot of potential – with pharmaceutical and vaccine companies that are huge suppliers all over the world. You know that more vaccines are made in India than anywhere – starting with the Serum Institute, that’s the biggest, ” They said.

9) Drug firm Zydus Cadila also said that it has begun human clinical trials of its COVID-19 vaccine candidate ZyCoV-D. In the trial phase, the company will enroll in more than 1,000 subjects at several clinical study sites in India, it said in a regulatory filing.

10) DCGI has allowed two vaccines – one by Bharat Biotech International Limited in collaboration with ICMR and the other by Zydas Cadila Healthcare Ltd to go into Phase I and II human clinical trials.